EUVIMEDScopri EUVIMED
Crossref

Novel 10‐Alkoxy 1,4‐Dien‐3‐One Estranes as Multitarget Anticancer Agents Against Estrogen‐Positive Breast Cancer

Ivana Kuzminac iD, Sofija Bekić iD, Milica Stevanović, Julia Scholda, Florian Kopp, Edward Petri, Anđelka Ćelić iD, Marija Sakač

Chemical Biology & Drug Design · 2026-05 · 107 (5)

DOI: 10.1111/cbdd.70321 ↗

At a glance

Journal article in Chemical Biology & Drug Design, published online on 2026-05-26. Written by Ivana Kuzminac and 7 co-authors. Institution: Faculty of Sciences, Department of Chemistry, Biochemistry and Environmental Protection, University of Novi Sad, Novi Sad, Serbia. Major MEDLINE topics: Breast Neoplasms, Antineoplastic Agents. 67 references. Funded by: the Ministry of Science, Technological Development and Innovation of the Republic of Serbia, the bilateral cooperation between the Republic of Austria and the Republic of Serbia.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Breast cancer remains the most prevalent cancer among women, driving the continuous search for novel anticancer agents. In this study, a series of 10‐alkoxy steroids containing a 1,4‐dien‐3‐one moiety was synthesized via a one‐step dearomatization of the A‐ring of estradiol and an estrane derivative with a D‐homo lactone moiety. All compounds exhibited favorable in silico ADMET properties, while five derivatives showed significant cytotoxic activity in vitro. The strongest effects against the estrogen‐positive breast cancer cell line MCF‐7 were observed for two 10β‐methoxy, one 10β‐butoxy, and two 10β‐propargyloxy derivatives. The activity of the 10β‐butoxy‐17β‐hydroxy and 10β‐propargyloxy‐17β‐hydroxy steroids correlates with strong binding affinity toward estrogen receptor α and inhibition of AKR1C3 and AKR1C4 enzymatic activity. Additionally, the propargyloxy derivative showed substrate‐like binding to human recombinant aromatase. Molecular docking results are in qualitative agreement with these findings, predicting binding modes similar to known ligands and possible hydrophobic interactions between the C‐10 alkoxy groups and the active sites of target proteins, particularly the heme group of aromatase. These results highlight novel estrane derivatives as promising candidates for estrogen‐positive breast cancer therapy through combined effects involving AKR1C3 inhibition and interaction with aromatase and estrogen receptor.

Subjects

MeSH terms (MEDLINE)

Breast NeoplasmsAntineoplastic AgentsHumansFemaleMolecular Docking SimulationMCF-7 CellsAldo-Keto Reductase Family 1 Member C3AromataseEstrogen Receptor alphaHydroxyprostaglandin DehydrogenasesEstrogensCell Line, TumorHydroxysteroid DehydrogenasesBinding SitesAromatase Inhibitors

Author keywords

ADMETAKR1Caromatasebreast cancercytotoxicitysteroids

Substances

Antineoplastic AgentsAldo-Keto Reductase Family 1 Member C3AKR1C3 protein, humanAromataseEstrogen Receptor alphaHydroxyprostaglandin DehydrogenasesEstrogensHydroxysteroid DehydrogenasesAromatase Inhibitors

Authors and institutions

  • Faculty of Sciences, Department of Chemistry, Biochemistry and Environmental Protection, University of Novi Sad, Novi Sad, Serbia.
  • Faculty of Life Sciences, Department of Pharmaceutical Sciences, Clinical Pharmacy Group, University of Vienna, Vienna, Austria.
  • Faculty of Sciences, Department of Biology and Ecology, University of Novi Sad, Novi Sad, Serbia.

ORCID profiles: Ivana Kuzminac, Sofija Bekić, Anđelka Ćelić

Funding

  • the Ministry of Science, Technological Development and Innovation of the Republic of Serbia
  • the bilateral cooperation between the Republic of Austria and the Republic of Serbia

Cite

APA

Kuzminac, I., Bekić, S., Stevanović, M., Scholda, J., Kopp, F., Petri, E., Ćelić, A., & Sakač, M. (2026). Novel 10‐Alkoxy 1,4‐Dien‐3‐One Estranes as Multitarget Anticancer Agents Against Estrogen‐Positive Breast Cancer. Chemical Biology & Drug Design, 107(5). https://doi.org/10.1111/cbdd.70321

Vancouver

Kuzminac I, Bekić S, Stevanović M, Scholda J, Kopp F, Petri E, et al. Novel 10‐Alkoxy 1,4‐Dien‐3‐One Estranes as Multitarget Anticancer Agents Against Estrogen‐Positive Breast Cancer. Chemical Biology & Drug Design. 2026;107(5). doi:10.1111/cbdd.70321

BibTeX
@article{Kuzminac2026,
  author = {Kuzminac, Ivana and Bekić, Sofija and Stevanović, Milica and Scholda, Julia and Kopp, Florian and Petri, Edward and Ćelić, Anđelka and Sakač, Marija},
  title = {Novel 10‐Alkoxy 1,4‐Dien‐3‐One Estranes as Multitarget Anticancer Agents Against Estrogen‐Positive Breast Cancer},
  journal = {Chemical Biology & Drug Design},
  year = {2026},
  volume = {107},
  number = {5},
  doi = {10.1111/cbdd.70321}
}
Start for free →